Migraine, Motivation, and the DTx Moment: What Makes Patients Stick with Digital Therapeutics
- Ifeanyi Esimai, MD
- Aug 7, 2025
- 3 min read
As prescription digital therapeutics gain traction, the challenge isn’t just tech or trials — it’s trust, behavior change, and adherence. Migraine is showing us what DTx must get right.
If you’ve ever treated someone with migraines — or suffered from them yourself — you know this: it’s not just pain, it’s life disruption. It’s missed work, broken routines, and the looming dread of the next hit.
Now, imagine telling that patient: “There’s an app for that.”
Welcome to Digital Therapeutics (DTx), where software isn’t just supporting care — it is the treatment. Click Therapeutics is one of the players leading that charge, with CT-132 — a digital therapy targeting migraine. And they’re not just playing with code. They’re running clinical trials, clearing FDA hurdles, and anchoring themselves in outcomes.
But here’s the truth: digital therapeutics won’t change healthcare unless people use them. That means understanding one thing — adherence.
The Migraine Use Case: High Impact, High Stakes
Migraines are episodic, disruptive, and deeply personal. That makes them perfect — and brutal — for testing DTx.
Patients are motivated in the moment, but not always between episodes.
Triggers are multifactorial: stress, sleep, food, hormones.
Success isn’t measured by elimination, but reduction — a tough sell when the goal is "fewer bad days," not "zero migraines."
That’s the behavioral terrain Click Therapeutics has to navigate. And it’s where smart clinical writing becomes a secret weapon.
Adherence Isn’t a UX Problem — It’s a Behavior Problem
Most DTx companies treat adherence like a UI challenge: reminders, gamification, nudges. That’s a Band-Aid. Real adherence requires:
Framing: Clinician-level content that connects the science with real-world benefit. Think: "This reduces your risk of missing your kid’s soccer game" — not "clinical endpoints."
Trust: Regulatory-aligned language that reassures without overwhelming. You’re writing for someone in pain, not a peer reviewer.
Momentum: Messaging that keeps people engaged after week 1. This is where most apps fall off — and where behaviorally intelligent content wins.
What Clinician-Writers Bring to the Table
Clinicians understand the nuances of adherence — not from theory, but from direct experience with patients. We’ve seen what gets in the way: pain cycles, app fatigue, life. Writing for DTx isn’t just about clean copy. It’s about clinical instinct, behavioral empathy, and regulatory fluency — in one voice.
That’s the edge a clinician-writer brings.
If I were writing for Click Therapeutics, I’d focus on:
Translating clinical trial outcomes into emotional value
Aligning app prompts with behavioral health principles
Making onboarding content feel like a conversation with a human — not an instruction manual
Example copy: "You’ve made it through the week without a migraine. That’s not luck — that’s progress. Stay on it. Your brain will thank you."
Or: "Skipped a day? No big deal. Tap in now — even 3 minutes can reset your rhythm."
That’s not just content. That’s coaching, grounded in medicine
Final Word: DTx Isn’t Just a Product — It’s a Relationship
CT-132’s clinical win is huge. But the bigger win? Getting a migraine sufferer to stick with a digital treatment long enough to feel it work.
That takes more than AI. More than FDA clearance. It takes words — the right ones.
If you're building DTx, write like the patient is reading. Because they are.
This article is an independent commentary inspired by Click Therapeutics’ work in digital therapeutics and migraine. For more, visit clicktherapeutics.com.
Interested in working together?
If you're building digital health solutions and need writing that bridges science, empathy, and behavior change — let’s talk.
Contact: Connect via LinkedIn Profile: Ifeanyi Esimai, MD
Comments